Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00022871
DRKS00022871
Recruiting
Not Applicable

Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ) - PROVID-CAPNETZ

CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover0 sites400 target enrollmentOctober 1, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronavirus Disease 19 (COVID-19)
Sponsor
CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover
Enrollment
400
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover

Eligibility Criteria

Inclusion Criteria

  • •Inclusion criteria (PROVID\-CAPNETZ):
  • •Age \= 18
  • •Radiological proof of infiltrate (primarily chest x\-ray or CT) with positive detection of SARS\-CoV\-2\-virus
  • •with no proven infiltrate with positive detection of SARS\-CoV\-2\-virus
  • •Informed consent signed

Exclusion Criteria

  • •Exclusion criteria (PROVID\-CAPNETZ):
  • •Newly diagnosed, active pulmonary tuberculosis within the last 2 months
  • •Simultaneous participation in PROVID\-PROGRESS or PROVID\-CAPSyS cohort
  • •Participation of the patient in PROVID\-PROGRESS or PROVID\-CAPSyS cohort at an earlier point in time

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)U07.1J12J13J14J15J16J17J18COVID-19, virus identifiedViral pneumonia, not elsewhere classifiedPneumonia due to Streptococcus pneumoniaePneumonia due to Haemophilus influenzaeBacterial pneumonia, not elsewhere classifiedPneumonia due to other infectious organisms, not elsewhere classifiedPneumonia in diseases classified elsewherePneumonia, organism unspecified
DRKS00023277Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation94
Recruiting
Not Applicable
Identification and analysis of biomarkers for the course of demyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosisDemyelinating and inflammatory diseases of the central nervous system, in particular multiple sclerosis
DRKS00031139MPI-NAT1,000
Recruiting
Not Applicable
Testing novel biomarkers for the diagnosis of the delayed sleep wake phase disorder (DSWPD) in young adultsG47Sleep disorders
DRKS00030981Charitè Universitätmedizin (Chronobiology Lab)32
Recruiting
Not Applicable
Discovery of Novel Biomarkers for the Diagnosis of TB DiseaseA15Respiratory tuberculosis, bacteriologically and histologically confirmed
DRKS00032445Roche360
Not yet recruiting
Not Applicable
Identification of biomarkers and pathogenesis of lung cancer without targeted metabolomics based on uplc-q-tof /MSung cancer
ITMCTR1900002555The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine